ASCO '23 Entrees
OncoPharm
00:00
Pemberlizumab Plus Chemo for Non-Small Cell Lung Cancer
keynote 671 is a new age of at Pemberlizumab plus chemo for, for non-small cell lung cancer. They are including a slightly different patient population, no one B, stage two, three, and three B. We see 18.1% pathologic complete response rate in this study. But we don't know what would happen if all those folks on placebo, all of them would have got OC Martin which we knew was better for years now.
Transcript
Play full episode
